Xenon Pharmaceuticals, a neuroscience-focused biopharmaceutical company, announced it will present at four investor conferences in Q4 2026, including events in Boston, New York, London, and Coral Gables. These presentations will feature fireside chats where the company will discuss its drug development progress, notably its lead molecule azetukalner for epilepsy and depression. Investors can access webcast replays on Xenon's website. This visibility aims to boost investor awareness ahead of upcoming financial results and ongoing clinical developments.
Xenon Pharmaceuticals is presenting at investor conferences this quarter. For readers following the health sector, here is Pluang's market snapshot as of Nov 04, 2026 04:11 WIB: Out of 150 priced US health stocks, 92 rose and 55 fell today. Notable movers include INO at USD 1.65 with a 12.96% drop, IOVA at USD 8.86 up 10.47%, and DNA at USD 10.74 up 9.04%.
Vencora has acquired CT InsureTech, a leading insurance technology provider with offices in London, Buenos Aires, and Mexico City. This acquisition strengthens Vencora's insurance technology offerings and expands its presence in Latin America and Eur...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
Atlanticus Holdings Corporation announced that its CEO Jeff Howard and CFO Bill McCamey will participate in the KBW Fintech Ecosystem Conference in New York from November 10-12, 2026. Jeff Howard will join a fireside chat titled “Beyond the Credit Sc...
United Fire Group reported a 10% decline in Q3 2026 net income to $35.1 million, or $1.34 per diluted share, despite a 13% increase in net written premiums driven by commercial business growth. The combined ratio rose to 94.6% from 91.9% due to highe...
Curaleaf Holdings reported third quarter 2026 net revenue of $353 million, up 11% year-over-year, driven by 8% domestic and 28% international growth. The company achieved an adjusted gross profit margin of 49% and adjusted EBITDA of $78 million, refl...
